September 30, 2024
Perseus Proteomics, Inc.
President & CEO: Takuya Yokokawa
e-mail: ir@ppmx.com

Announcement of Abstract of PPMX-T002 Presentation at EANM'24 Annual Congress

Perseus Proteomics Inc. ("the Company") is pleased to announce that the abstract of the presentation of PPMX-T002, a radioisotope labelled antibody under development led by the Company, has been published for the EANM (European Association of Nuclear Medicine)'24 in Hamburg, Germany.

Title: Preclinical evaluation of Cadherin 3 (CDH3)-targeted alpha radiopharmaceutical therapy, ^{225}Ac-PPMX-T002 for the treatment of solid cancer
Date: October 19 – 23, 2024
Download URL: https://eanm24.eanm.org/abstractsubmission/abstract-book/

PPMX-T002 is a radioisotope labelled antibody against cadherin 3 (CDH3), which is expressed on solid tumors including head and neck, ovarian, pancreatic and lung cancers. The Company has been developing the antibody under a strategy to change the radioisotope from Yttrium 90 (^{90}Y), a beta emitter, to Actinium 225 (^{225}Ac), an alpha emitter. In the animal experiments using mice with human pancreatic cancer cells transplanted, it was shown that ^{225}Ac-labelled antibody exhibited more remarkable efficacy compared with ^{90}Y-labelled antibody.

END